Navigation Links
Proove CEO and Vice Chairman of the Howard County Board of Education, Brian Meshkin, Selected as one of Howard County's Finest Under 39 by the Cystic Fibrosis Foundation
Date:9/24/2013

Irvine, CA (PRWEB) September 24, 2013

Proove Biosciences Inc., the leading personalized pain medicine laboratory, is proud to announce CEO Brian Meshkin has been selected as one of Howard County’s Finest Under 39. Meshkin is also the Vice Chairman of the Howard County Board of Education, and an avid supporter of causes to improve the lives of others.

The event honors young professionals who have demonstrated success in business, leadership in the community, and who are committed to fundraising for the Cystic Fibrosis Foundation. The event will be held on November 6, 2013 at 6pm, at the Turf Valley Resort and Conference Center.

The Maryland Chapter of the CFF is consistently a leader within the foundation through active volunteer participation and substantial fund-raising successes. Maryland Chapter volunteers plan, organize, and implement various fund raising projects throughout the year. The Finest Under 39 event will recognize honorees as prominent business leaders in the community, facilitate excellent networking opportunities, and promote fund raising towards helping to find a cure for Cystic Fibrosis.

“It is an incredible honor to be nominated by the CFF for this designation. The team at Proove Biosciences works hard to ensure we continue to produce industry leading research, as well as the tools that pain treatment professionals rely on daily,” stated Meshkin. “As the CEO of Proove, I understand the importance of genetic research, and will continue to support the efforts of the CFF in finding a cure for this disease.”

Cystic fibrosis is a devastating genetic disease that affects the lungs and digestive system. More than ten million Americans are symptomless carriers of the defective CF gene. Advances continue to be made in finding a cure, but help is needed now -- more than ever -- to help keep up the momentum of this life-saving research. When the Foundation began in 1955, most children with CF did not live to see their first day of elementary school. Today, the median predicted age of survival for a person with CF is in the mid-30s. This is remarkable progress, but not good enough. To learn more about CF and the CF Foundation, visit http://www.cff.org. To make a contribution to support this important research and support Brian’s fundraising effort, click here.

About Proove Biosciences
Proove Biosciences is a Personalized Pain Medicine company that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. Based in Southern California, physicians use Proove testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove Biosciences performs proprietary genetic tests in a CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/9/prweb11156213.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
2. Sanomedics International Holdings, Inc. appoints new Chairman of the Board and installs new Director of Business Development.
3. James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
4. Microvi Biotechnologies Appoints Former COO of Zenon Environmental as Chairman of Board of Directors
5. Exosome Diagnostics Names Kapil Dhingra Chairman of the Board of Directors
6. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
7. Life Technologies Chairman And CEO Gregory T. Lucier Named Penn State Outstanding Engineering Alumnus
8. GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
9. Ernest Mario, Ph.D., Named Chairman of Chimerix, Inc.
10. VIASPACE Chairman and CEO Attend EUEC 2013, Giant King Grass Prominently Featured in Convention Exhibit Hall
11. California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... The Fight Against Cancer Innovation Trust (FACIT) and the ... report that Fusion Pharmaceuticals Inc. (Fusion) has closed a ... – JJDC, Inc. (JJDC) as the lead investor. Additional, ... and Genesys Capital, as well as founding investor FACIT.  ... ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... , Feb. 23, 2017  Imanis Life ... product line of oncolytic vaccinia viruses for virotherapy ... as part of Genelux,s proprietary, vaccinia virus-based technology ... excited to enter into a partnership with Genelux ... oncolytic vaccinia viruses for use in research," said ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... that in a published evaluation of multiple immunoassay-based threat detection technologies by ... Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found to have ...
Breaking Biology Technology:
(Date:2/7/2017)... MINNETONKA, Minn. , Feb. 7, 2017   ... that supports the entire spectrum of clinical research, is ... iMedNet , its innovative, highly flexible and ... iMedNet customers. iMedNet is a ... only provides Electronic Data Capture (EDC), but also delivers ...
(Date:2/3/2017)... Feb. 3, 2017 A new independent identity ... Partners, LLP (IdSP) . Designed to fill a critical ... identity market, founding partners Mark Crego and ... years just in identity expertise that span federal governments, ... leadership. The Crego-Kephart combined expertise has a common theme ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
Breaking Biology News(10 mins):